We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

P3 (Prepared, Protected, emPowered) (P3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03320512
Recruitment Status : Completed
First Posted : October 25, 2017
Results First Posted : September 19, 2022
Last Update Posted : October 25, 2022
Sponsor:
Collaborators:
Emory University
Duke University
Children's Hospital of Philadelphia
The Fenway Institute
Montefiore Hospital
Baylor College of Medicine
Ruth M. Rothstein CORE Center
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
University of South Florida
Information provided by (Responsible Party):
University of North Carolina, Chapel Hill

Brief Summary:
P3 (Prepared, Protected, emPowered) is an interactive smartphone app for HIV-uninfected YMSM and YTW that utilizes social networking and game-based mechanics as well as a comprehensive understanding of what constitutes "best practices" in app development to improve PrEP adherence and persistence in PrEP care.

Condition or disease Intervention/treatment Phase
Sexually Transmitted Diseases Safe Sex Adherence, Medication Behavioral: P3 Behavioral: P3+ Behavioral: Control Not Applicable

Detailed Description:

Sustainable, integrated PrEP adherence interventions are critically needed to reduce HIV incidence among YMSM and YTW. It is imperative that the investigators develop adherence interventions for YMSM and YTW initiating PrEP that are engaging, age-appropriate and take advantage of technologies that are already embedded in these individual's lives. A smartphone-delivered PrEP adherence intervention is well suited for this population, given they have a high-uptake and utilization of smartphone technology. The use of smartphones to deliver HIV prevention and care interventions has grown substantially in recent years due to: a) wide-scale adoption of smartphone technology among high-risk groups, b) the ability to deliver interventions in real-time within risk contexts, and c) low implementation costs.The accessibility, affordability, anonymity and acceptability of smartphones make them the intervention medium of choice for engaging youth and a logical platform to deliver an adherence intervention targeting PrEP. Further, smartphone interventions address can overcome issues that impede engagement with in-person interventions such as transportation logistics, stigma and confidentiality. Further youth, including YMSM and YTW are receptive to smartphone delivered interventions and these interventions can impact HIV related prevention behaviors.

P3 (Prepared, Protected, emPowered) is an interactive smartphone app for HIV-uninfected YMSM and YTW that utilizes social networking and game-based mechanics as well as a comprehensive understanding of what constitutes "best practices" in app development to improve PrEP adherence and persistence in PrEP care. Built on a successful, evidence-based platform designed and tested by our collaborating technology partner, Ayogo, P3 is flexible and responsive to changes in technology. This flexibility will also allow us to quickly respond to and modify our intervention to align with emerging PrEP practice standards and guidelines.

Despite the benefits of app-based interventions, maintaining engagement over time can be particularly challenging. Lack of rapport building may contribute to lower retention rates in technology-based interventions. Further, the available literature suggests that some tools, including technology based tools, may be more beneficial to patient adherence when combined with education or counseling. To investigate this possibility, the investigators will include a study arm (P3+) that includes P3 and adherence counseling delivered by a counselor through the P3 app.

This study has three phases, usability testing, field testing, and a randomized-controlled trial (RCT). In usability testing the investigators will test beta versions of the app and gain feedback about the intervention from the target population, identify any technical issues, and get feedback on app content. Field testing is to ensure that the features, platform and content of P3 and P3+ are acceptable to the target population and that there are no technical challenges or user concerns with either the app, the dried blood spot (DBS), hair, or mitra sampling collection.

The last phase is a three arm, RCT that will test the efficacy of P3, a novel, theory-based mobile app that utilizes game mechanics and social networking features to improve PrEP adherence, retention in PrEP clinical care, and PrEP persistence among young men who have sex with men (YMSM) and young trans women (YTW) who have sex with men, ages 16-24. The investigators will test the efficacy of P3 and P3+, which adds Next Step Counseling delivered by an adherence counselor through the app, against PrEP standard of care. Participants will be randomized to P3, P3+, or standard of care. A cost comparison between P3 and P3+ will be conducted.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 246 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Intervention Model Description: The trial will consist of a three-arm RCT to test intervention efficacy among young men who have sex with men (YMSM) and young transgender women who have sex with men (YTWSM) who are starting PrEP or are non-adherent to PrEP. Study arms will include P3, P3+, and standard of care (SOC). Participants will be recruited from seven cities. The investigators will enroll up to 240 participants and randomize them 1:1:1 to receive P3, P3+, or SOC. Assessments will be completed at months 0, 3, and 6.
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: P3 (Prepared, Protected, emPowered): Promoting Pre-exposure Prophylaxis (PrEP) Adherence Through a Social Networking, Gamification, and Adherence Support App
Actual Study Start Date : May 15, 2019
Actual Primary Completion Date : September 16, 2021
Actual Study Completion Date : September 16, 2021

Arm Intervention/treatment
Experimental: P3
Participants will use P3
Behavioral: P3
P3 is an interactive smartphone app that utilizes social networking and game-based mechanics to improve PrEP adherence and persistence in PrEP care. The participant will install P3 on their phone, receive a guided tour of the app and a reminder card with the research coordinator's phone number and email address and instructed to contact the research coordinator immediately to report difficulties with any app components or to report any problems with their phone or phone service. A help link is embedded within the app that directly links to study staff if assistance is needed. P3 arm participants will have 24-hour access to all features of P3.
Other Name: Prepared, Protected, emPowered

Experimental: P3+
Participants will use P3+
Behavioral: P3+
In P3+, participants receive all of P3 and the ability to text in the app with an adherence counselor, using Next Step Counseling (NSC). NSC is an interactive, client-centered motivational intervention to improve PrEP adherence. Key components of NSC include: review experiences with adherence, exploration of adherence facilitators and barriers, identification of adherence needs, identification of strategies to meet needs, and development of an adherence action plan. Participants will install P3+ on their phone. The adherence counselor feature will be unlocked for those in the P3+ arm. P3+ participants will have 24-hour access to all features of P3+.

Placebo Comparator: Control
Participants will receive the standard of care
Behavioral: Control
Control participants will receive the standard of care for receiving a prescription for PrEP.




Primary Outcome Measures :
  1. PrEP Adherence Defined by Tenofovir Diphosphate (P3 and P3+ vs Control) [ Time Frame: Month 3, Month 6 ]
    PrEP adherence is measured by blood sample levels of tenofovir diphosphate (TFV-DP) with blood concentration consistent with > 4 doses/week at 3- and 6- month follow-ups. The estimation of the average treatment effect compared P3 and P3+ combined to Control.

  2. PrEP Adherence Defined by Emtricitabine Triphosphate (P3 and P3+ vs Control) [ Time Frame: Month 3, Month 6 ]
    PrEP adherence is measured by blood sample levels of emtricitabine triphosphate (FTC-TP) with blood concentration consistent with > 4 doses/week at 3- and 6- month follow-ups. The estimation of the average treatment effect compared P3 and P3+ combined to Control.


Secondary Outcome Measures :
  1. Number of Participants With Self-reported Retention in PrEP Clinical Care [ Time Frame: Month 3, Month 6 ]
    The investigators define "retention in care" as at least 1 PrEP clinical visit occurring in the last 3 months.

  2. PrEP Persistence [ Time Frame: Month 3, Month 6 ]
    PrEP persistence will be measured by self-report at follow up of current PrEP use.

  3. Insertive Condomless Anal Sex [ Time Frame: Month 3, Month 6 ]
    Sexual Practices were assessed by self-reported number of insertive condomless anal sex occurrences during the past 3 months. This question is asked at the 3- and 6-month follow-up surveys.

  4. Receptive Condomless Anal Sex [ Time Frame: Month 3, Month 6 ]
    Sexual Practices were assessed by self-reported number of receptive condomless anal sex occurrences during the past 3 months. This question is asked at the 3- and 6-month follow-up surveys.

  5. Sexually Transmitted Infections (STI) Incidence [ Time Frame: Month 3, Month 6 ]
    Self-reported STIs (combined rectal and urethral gonorrhea and chlamydia, syphilis) in last 3 months. This question is asked at the 3- and 6-month follow-up surveys.

  6. PrEP Adherence Defined by Tenofovir Diphosphate (P3 vs Control and P3+ vs Control) [ Time Frame: Month 3, Month 6 ]
    PrEP adherence is measured by blood sample levels of tenofovir diphosphate (TFV-DP) with blood concentration consistent with > 4 doses/week at 3- and 6- month follow-ups. The estimation of the average treatment effect compared P3 to Control and also P3+ to Control.

  7. PrEP Adherence Defined by Emtricitabine Triphosphate (P3 vs Control and P3+ vs Control) [ Time Frame: Month 3, Month 6 ]
    PrEP adherence is measured by blood sample levels of emtricitabine triphosphate (FTC-TP) with blood concentration consistent with > 4 doses/week at 3- and 6- month follow-ups. The estimation of the average treatment effect compared P3 to Control and also P3+ to Control.

  8. Self-Reported Weekly PrEP Use [ Time Frame: Month 3, Month 6 ]
    Number of participants reported taking their PrEP medication >/= 4 days in the past week.

  9. Self-Reported Monthly PrEP Use [ Time Frame: Month 3, Month 6 ]
    Median self-reported percent of time in the past month that participants' took their PrEP as prescribed.

  10. Mean Site-Level Intervention Cost [ Time Frame: Throughout the duration of the study, approximately 1.5 years ]
    Information was collected on (1) time spent by study staff for training and supervision of adherence counselor(s); (2) time participants spent in the adherence counseling sessions; and (3) costs associated with the delivery of both P3 and P3+. Resources were organized into standard expenditure categories and attributed to the corresponding P3 or P3+ arm and study site as appropriate.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years to 24 Years   (Child, Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Self-identify as MSM or TW who has sex with men
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Are aged 16-24
  • Were assigned male sex at birth
  • Report sex with men or transgender women
  • Are able to speak and read English
  • Have reliable daily access to an Android or iOS smartphone with a data plan
  • Are HIV-uninfected (self-report)
  • Are not currently on PrEP but plan to initiate in the next 7 days and have an active PrEP prescription (prescription confirmed by study staff) OR on PrEP have an active PrEP prescription (prescription confirmed by study staff)
  • Recruited from one of 9 subject recruitment venues (SRV) cities (Atlanta, Georgia; Boston, Massachusetts; Bronx, New York; Chicago, Illinois; Houston, Texas; Philadelphia, Pennsylvania; Tampa, Florida; Chapel Hill, NC; Charlotte, NC)

Exclusion Criteria:

  • Aged younger than 15 years or older than 24 years
  • Not available to meet with project staff for planned study visit(s)
  • Non-English speaking
  • Living with HIV
  • Not currently prescribed PrEP (study staff unable to verify participant has an active PrEP prescription by a health provider)
  • Anticipate not having reliable access to a smartphone with a data plan for 2 or more days during field testing or 1 or more weeks during the RCT intervention period
  • Planning to move out of study area during the study period
  • Unwilling or unable to comply with protocol requirements.
  • Participated in field trial phase of P3 study
  • Unable to be consented due to active substance use or psychological condition.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03320512


Locations
Layout table for location information
United States, Florida
University of South Florida Infectious Diseases
Tampa, Florida, United States, 33606
United States, Georgia
PRISM Health
Atlanta, Georgia, United States, 30322
United States, Illinois
The Adolescent and Young Adult Research (AYAR) at the CORE Center
Chicago, Illinois, United States, 60612
United States, Massachusetts
The Fenway Institute
Boston, Massachusetts, United States, 02215
United States, New York
Children's Hospital at Montefiore
Bronx, New York, United States, 10467
United States, North Carolina
UNC-Chapel Hill
Chapel Hill, North Carolina, United States, 27599
RAIN
Charlotte, North Carolina, United States, 29202
United States, Pennsylvania
Adolescent Initiative at Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
United States, Texas
Texas Children's Hospital
Houston, Texas, United States, 77030
Sponsors and Collaborators
University of North Carolina, Chapel Hill
Emory University
Duke University
Children's Hospital of Philadelphia
The Fenway Institute
Montefiore Hospital
Baylor College of Medicine
Ruth M. Rothstein CORE Center
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
University of South Florida
Investigators
Layout table for investigator information
Principal Investigator: Lisa Hightow-Weidman, MD UNC Chapel Hill
  Study Documents (Full-Text)

Documents provided by University of North Carolina, Chapel Hill:
Study Protocol  [PDF] July 11, 2022
Statistical Analysis Plan  [PDF] July 21, 2022

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier: NCT03320512    
Other Study ID Numbers: 17-1951
5U19HD089881-02 ( U.S. NIH Grant/Contract )
First Posted: October 25, 2017    Key Record Dates
Results First Posted: September 19, 2022
Last Update Posted: October 25, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of North Carolina, Chapel Hill:
PrEP
gamification
mHealth
HIV prevention
truvada
eHealth
app
adherence
ymsm
transgender women
Additional relevant MeSH terms:
Layout table for MeSH terms
Sexually Transmitted Diseases
Communicable Diseases
Infections
Genital Diseases
Urogenital Diseases
Disease Attributes
Pathologic Processes